Spiramide (AMI-193) is a spiperone derivative, a selective 5-HT2A, (Ki = 2 nM) 5-HT1A (Ki = 50 nM), and D2 receptor (Ki = 3 nM) antagonist, with negligible affinity for the 5-HT2C receptor (Ki = 4300 nM). The ability of Spiramide to serve as a functional 5-HT2A antagonist in behavioral studies was demonstrated through studies in which Spiramide blocked the discriminative - stimulus effects of the 5HT2A agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM).

Triampyzine is an anticholinergic, antisecretory agent.

Tenamfetamine (also known as 3,4-methylenedioxyamphetamine (or MDA)) is a hallucinogen that acts as a serotonergic 5-HT2A receptor agonist and releases monoamines by interacting with monoamine plasmalemmal transporters. Tenamfetamine had no accepted medical use and it was scheduled as a controlled substance in the US in 1970. Despite appearing in illicit drug preparations, tenamfetamine has not been studied in humans in over 30 years. In 2010 was published article where was described the action of tenamfetaminea in a clinical trial in humans. In this trial was shown that the drug had induced mystical-type experiences and, in at least some individuals, closed-eye visions. However, during that experiment were impossible to provide strong evidence for changes in the efficacy of top-down influences on perception or acutely increased occipital cortex excitation.

Feclemine is a spasmolytic agent.

Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.

Ilepcimide, a piperine derivative, was studied in China as an anticonvulsant agent for the treatment of seizures in epilepsy children patients. However, this study was discontinued.

Ciclactate is cyclohexanol derivative patented by N. V. Koninklijke Pharmaceutische Fabrieken Voorheen Brocades-Stheeman & Pharmacia as spasmolytics and blood vessel dilator. Ciclactate has never been marketed in the US and EU.

Metacetamol (3-hydroxyacetanilide) is a structural isomer of the widely used drug paracetamol and is being considered as a promising alternative to the latter because of its lower toxicity. 3-hydroxyacetanilide, the positional isomer of paracetamol, does not cause depletion of GSH in vivo or hepatotoxicity even though the extent of covalent binding of the reactive metabolite (in vivo or in vitro) is comparable to that for an equimolar dose of paracetamol. Metacetamol should prove to be a useful tool to aid in the discrimination of hepatic acetaminophen protein adducts that may be critical or noncritical to survival of hepatocytes

(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)-3-PPP, also known as preclamol) has a dual action towards to dopamine D2 autoreceptor: it activates it and also acts concomitantly as an antagonist at postsynaptic DA receptors. It was shown, that (-)-3PPP/preclamol was a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy. Besides, the motor effects of the drug were evaluated in nine patients with Parkinson's disease using a double-blind, placebo-controlled design. However, the small number of patients manifesting a clinically significant response and the frequently inconsistent effects could indicate that this class of agents may have relatively limited clinical utility.

Decimemide is a spasmolytic and anticonvulsant derivative of benzamide, developed by the Hungarian E.G.Y.R Gyogyszervegyeszeti Gyar. The compound is claimed to effectively inhibit convulsion caused by chemoconvulsants or electric shock and to have a strong antiepileptic effect without showing any neurodepressant character.